116 related articles for article (PubMed ID: 27035013)
1. Retraction notice to “Antiviral and myocyte protective effects of IL-28A in coxsackievirus B3-induced myocarditis” [Braz. J. Infect. Dis. (2015) 132–140].
Wang S; Huang X; Zhang J; Huang C
Braz J Infect Dis; 2015; 19(6):678. PubMed ID: 27035013
[No Abstract] [Full Text] [Related]
2. Oxymatrine provides protection against Coxsackievirus B3-induced myocarditis in BALB/c mice.
Jiang Y; Zhu Y; Mu Q; Luo H; Zhi Y; Shen X
Antiviral Res; 2017 May; 141():133-139. PubMed ID: 28115196
[TBL] [Abstract][Full Text] [Related]
3. Retraction notice to “The rapid and sustained responses of dendritic cells to influenza virus infection in a non-human primate model” [Braz. J. Infect. Dis. 18 (2014) 406–413].
Jie Z; Sun W; Wang S; Koster F; Li B; Harrod KS
Braz J Infect Dis; 2015; 19(6):677. PubMed ID: 27030851
[No Abstract] [Full Text] [Related]
4. Nicotine inhibits the production of proinflammatory cytokines of mice infected with coxsackievirus B3.
Li-Sha G; Jing-Lin Z; Li L; Guang-Yi C; Xiao-Wei L; Yue-Chun L
Life Sci; 2016 Mar; 148():9-16. PubMed ID: 26851533
[TBL] [Abstract][Full Text] [Related]
5. Human induced pluripotent stem cell-derived cardiomyocytes as an in vitro model for coxsackievirus B3-induced myocarditis and antiviral drug screening platform.
Sharma A; Marceau C; Hamaguchi R; Burridge PW; Rajarajan K; Churko JM; Wu H; Sallam KI; Matsa E; Sturzu AC; Che Y; Ebert A; Diecke S; Liang P; Red-Horse K; Carette JE; Wu SM; Wu JC
Circ Res; 2014 Aug; 115(6):556-66. PubMed ID: 25015077
[TBL] [Abstract][Full Text] [Related]
6. Nitric oxide and murine coxsackievirus B3 myocarditis: aggravation of myocarditis by inhibition of nitric oxide synthase.
Hiraoka Y; Kishimoto C; Takada H; Nakamura M; Kurokawa M; Ochiai H; Shiraki K
J Am Coll Cardiol; 1996 Nov; 28(6):1610-5. PubMed ID: 8917278
[TBL] [Abstract][Full Text] [Related]
7. Fasudil exerts a cardio-protective effect on mice with coxsackievirus B3-induced acute viral myocarditis.
Dai K; Wang Y; Tai S; Ni H; Lian H; Yu Y; Liao W; Zheng C; Chen Q; Kuver A; Li J
Cardiovasc Ther; 2018 Dec; 36(6):e12477. PubMed ID: 30380183
[TBL] [Abstract][Full Text] [Related]
8. Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb/c mice.
Wang YX; da Cunha V; Vincelette J; White K; Velichko S; Xu Y; Gross C; Fitch RM; Halks-Miller M; Larsen BR; Yajima T; Knowlton KU; Vergona R; Sullivan ME; Croze E
Am J Physiol Heart Circ Physiol; 2007 Jul; 293(1):H69-76. PubMed ID: 17434974
[TBL] [Abstract][Full Text] [Related]
9. Coxsackievirus B3 infection induced viral myocarditis by regulating the expression pattern of chemokines in cardiac myocytes.
Shen Y; Kan QC; Xu W; Chu YW; Xiong SD
Iran J Allergy Asthma Immunol; 2009 Mar; 8(1):1-9. PubMed ID: 19279353
[TBL] [Abstract][Full Text] [Related]
10. Cytokine profiles in heart, spleen, and thymus during the acute stage of experimental coxsackievirus B3-induced chronic myocarditis.
Schmidtke M; Glück B; Merkle I; Hofmann P; Stelzner A; Gemsa D
J Med Virol; 2000 Aug; 61(4):518-26. PubMed ID: 10897072
[TBL] [Abstract][Full Text] [Related]
11. Coxsackievirus B3 murine myocarditis: a pathologic spectrum of myocarditis in genetically defined inbred strains.
Herskowitz A; Wolfgram LJ; Rose NR; Beisel KW
J Am Coll Cardiol; 1987 Jun; 9(6):1311-9. PubMed ID: 3034991
[TBL] [Abstract][Full Text] [Related]
12. Coxsackievirus B3 infection leads to cell death of cardiac myocytes.
Herzum M; Ruppert V; Küytz B; Jomaa H; Nakamura I; Maisch B
J Mol Cell Cardiol; 1994 Jul; 26(7):907-13. PubMed ID: 7966359
[TBL] [Abstract][Full Text] [Related]
13. Early Treatment of Coxsackievirus B3-Infected Animals With Soluble Coxsackievirus-Adenovirus Receptor Inhibits Development of Chronic Coxsackievirus B3 Cardiomyopathy.
Pinkert S; Dieringer B; Klopfleisch R; Savvatis K; Van Linthout S; Pryshliak M; Tschöpe C; Klingel K; Kurreck J; Beling A; Fechner H
Circ Heart Fail; 2019 Nov; 12(11):e005250. PubMed ID: 31718319
[TBL] [Abstract][Full Text] [Related]
14. Comparison of effects of ivabradine versus carvedilol in murine model with the Coxsackievirus B3-induced viral myocarditis.
Yue-Chun L; Teng Z; Na-Dan Z; Li-Sha G; Qin L; Xue-Qiang G; Jia-Feng L
PLoS One; 2012; 7(6):e39394. PubMed ID: 22761780
[TBL] [Abstract][Full Text] [Related]
15. Amyocarditic coxsackievirus B3 causes myocarditis in immunocompromised mice.
Takada H; Kishimoto C; Kurokawa M; Hiraoka Y
Exp Clin Cardiol; 2003; 8(2):71-5. PubMed ID: 19641653
[TBL] [Abstract][Full Text] [Related]
16. Enhanced detection of cardiac myocyte damage by polarized light microscopy. Use in a model of coxsackievirus B3-induced myocarditis.
Chow LH; Boughner DR; Dunmore-Buyze J; Finlay H; Pickering JG
Cardiovasc Pathol; 2001; 10(2):83-6. PubMed ID: 11425601
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-27 ameliorates coxsackievirus-B3-induced viral myocarditis by inhibiting Th17 cells.
Zhu H; Lou C; Liu P
Virol J; 2015 Nov; 12():189. PubMed ID: 26578236
[TBL] [Abstract][Full Text] [Related]
18. Combination of RNA interference and virus receptor trap exerts additive antiviral activity in coxsackievirus B3-induced myocarditis in mice.
Stein EA; Pinkert S; Becher PM; Geisler A; Zeichhardt H; Klopfleisch R; Poller W; Tschöpe C; Lassner D; Fechner H; Kurreck J
J Infect Dis; 2015 Feb; 211(4):613-22. PubMed ID: 25193982
[TBL] [Abstract][Full Text] [Related]
19. [The analysis of T cell receptor Vbeta gene usage of cytolytic T-lymphocytes in coxsackievirus B3-induced myocarditis].
Wang YB; Hua YM; Shi XQ; Yang Y; Wei DP
Sichuan Da Xue Xue Bao Yi Xue Ban; 2006 Jan; 37(1):80-3. PubMed ID: 16468649
[TBL] [Abstract][Full Text] [Related]
20.
Lee YG; Park JH; Jeon ES; Kim JH; Lim BK
J Microbiol Biotechnol; 2016 Nov; 26(11):2012-2018. PubMed ID: 27558433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
